KR960700749A - RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE - Google Patents

RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE Download PDF

Info

Publication number
KR960700749A
KR960700749A KR1019950703810A KR19950703810A KR960700749A KR 960700749 A KR960700749 A KR 960700749A KR 1019950703810 A KR1019950703810 A KR 1019950703810A KR 19950703810 A KR19950703810 A KR 19950703810A KR 960700749 A KR960700749 A KR 960700749A
Authority
KR
South Korea
Prior art keywords
ebv
polypeptide
protein
mammal
pharmaceutically acceptable
Prior art date
Application number
KR1019950703810A
Other languages
Korean (ko)
Inventor
프라카시 라메시
Original Assignee
찰즈 디. 에버트
테라테크 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 찰즈 디. 에버트, 테라테크 인코오퍼레이티드 filed Critical 찰즈 디. 에버트
Publication of KR960700749A publication Critical patent/KR960700749A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 EBV의 gp350/220의 66kd 세린- 및 트레오닌-풍부영역에 기초한 재조합 플리펩티드 및 재조합 폴리펩티드 gp350/220을 제공한다. 그러한 폴리펩티드는 엡스타인-바르바이러스(EBV) 감염에 대하여 효과적인 백신으로서 유용하다.The present invention provides recombinant polypeptides and recombinant polypeptides gp350 / 220 based on the 66kd serine- and threonine-rich regions of gp350 / 220 of EBV. Such polypeptides are useful as effective vaccines against Epstein-Barrvirus (EBV) infection.

Description

제조합 엡스타인-바르 바이러스 단백질 및 그것의 백신에의 이용 (RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE)RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (27)

EBV의 gp350/220의 66kd 세린- 및 트레오닌-풍부영역 또는 포유동물에서 EBV-중화항체를 유도할 수 있는 그것의 단편으로 본질적으로 구성되는 실질적으로 순수한 폴리펩티드66kd serine- and threonine-rich regions of gp350 / 220 of EBV or substantially pure polypeptides consisting essentially of fragments thereof capable of inducing EBV-neutralizing antibodies in mammals 제1항의 글리코실화된 폴리펩티드.The glycosylated polypeptide of claim 1. 제약학적으로 허용가능한 담체와 혼합된 제2항의 폴리펩티드의 면역원성 양만큼을 함유하는 백신조성물Vaccine composition containing an immunogenic amount of the polypeptide of claim 2 in admixture with a pharmaceutically acceptable carrier EBV감염으로부터 포유동물은 보호하는 방법에 있어서, 제약학적으로 허용가능한 담체와 혼합된 제2항의 폴리펩티드의 면역원성 양만큼은 함유하는 백신조성물의 면역학적으로 유효한 투여량을 상기 포유동물에 투여하는 것을 이루어지는 방법A method of protecting a mammal from an EBV infection, comprising administering to said mammal an immunologically effective dosage of a vaccine composition containing an immunogenic amount of the polypeptide of claim 2 mixed with a pharmaceutically acceptable carrier. Way 제1항의 폴리펩티드를 암호화하는 핵산서열.A nucleic acid sequence encoding the polypeptide of claim 1. 제1항의 폴리펩티드를 암호화하는 핵산서열 및 상기 핵산에 작동적으로 연결되고 세포에서 상기핵산의 발현을 일으키는데 효과적인 발현조절서열을 함유하는 발현백터.An expression vector containing a nucleic acid sequence encoding the polypeptide of claim 1 and an expression control sequence operatively linked to the nucleic acid and effective for causing expression of the nucleic acid in a cell. 제6항의 발현벡터를 포함하는 세포.A cell comprising the expression vector of claim 6. 폴리펩티드의 생성을 허용하는 조건하에서 제7항의 세포를 생장시키는 것으로 이루어지는 폴리펩티드의 생성방법A method for producing a polypeptide, comprising growing the cell of claim 7 under conditions that permit the production of the polypeptide. 제약학적으로 허용가능한 담체와 혼합된 제1항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물.A vaccine composition containing an immunogenic amount of the polypeptide of claim 1 in admixture with a pharmaceutically acceptable carrier. EBV감염으로부터 포유동물을 보호하는 방법에 있어서, 제약학적으로 허용가능한 담체와 혼합된 제1항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물의 면역학적으로 유효한 투여량을 상기 포유동물에 투여하는 것으로 이루어지는 방법A method of protecting a mammal from an EBV infection, the method comprising administering to said mammal an immunologically effective dose of a vaccine composition containing an immunogenic amount of the polypeptide of claim 1 mixed with a pharmaceutically acceptable carrier. Way EBV의 gp350/220의 66kd 세린- 및 트레오닌- 풍부 영역 또는 그것의 단편 및 포유동물에서 EBV-중화항체를 유발할 수 있고 EBV결합과 B- 세포속으로의 도입을 억제할 수 있는 펩티드서열 Glu-Asp-Pro-Gly-Phe=Asn-Val-Glu를 함유하는 실질적으로 순수한 폴리펩티드Peptide sequence Glu-Asp capable of inducing EBV-neutralizing antibodies and inhibiting EBV binding and introduction into B-cells in the 66kd serine- and threonine-rich regions or fragments thereof of gp350 / 220 of EBV and mammals Substantially pure polypeptide containing -Pro-Gly-Phe = Asn-Val-Glu EBV감염으로부터 포유동물에 보호하는 방법에 있어서, 제약학적으로 허용가능한 담체와 혼합된 제11항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물의 면역학적으로 유효한 투여량을 상기 포유동물에 투여하는 것으로 이루어지는 방법A method of protecting a mammal from an EBV infection comprising administering to said mammal an immunologically effective dosage of a vaccine composition containing an immunogenic amount of the polypeptide of claim 11 in admixture with a pharmaceutically acceptable carrier. Way 제11항의 글리코실화된 폴리펩티드The glycosylated polypeptide of claim 11 EBV감염으로부터 포유동물에 보호하는 방법에 있어서, 제약학적으로 허용가능한 담체와 혼합된 제13항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물의 면역학적으로 유효한 투여량을 상기 포유동물에 투여하는 것으로 이루어지는 방법A method of protecting a mammal from EBV infection, comprising administering to said mammal an immunologically effective dosage of a vaccine composition containing an immunogenic amount of the polypeptide of claim 13 mixed with a pharmaceutically acceptable carrier. Way 제약학적으로 허용가능한 담체와 혼합된 제13항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물Vaccine composition containing an immunogenic amount of the polypeptide of claim 13 in admixture with a pharmaceutically acceptable carrier 제11항의 폴리펩티드를 암호화하는 핵산서열Nucleic acid sequence encoding the polypeptide of claim 11 제11항의 폴리펩티드를 암호화하는 핵산서열 및 상기 핵산에 작동적으로 연결되고 세포에서 상기 핵산의 발현을 일으키는데 효과적인 발현조절서열을 함유하는 발현벡터.An expression vector containing a nucleic acid sequence encoding the polypeptide of claim 11 and an expression control sequence operatively linked to the nucleic acid and effective for causing expression of the nucleic acid in a cell. 제17항의 발현벡터를 포함하는 세포Cell containing the expression vector of claim 17 폴리펩티드의 생성을 허용하는 조건하에서 제18항의 세포를 생장시키는 것으로 이루어지는 폴리ㅔㅂ티드의 생성방법A method for producing a polytide, comprising growing the cells of claim 18 under conditions that allow the production of a polypeptide. 제약학적으로 허용가능한 담체와 혼합된 제11항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물Vaccine composition containing an immunogenic amount of the polypeptide of claim 11 in admixture with a pharmaceutically acceptable carrier 실질적으로 순수한 EBV gp350/220단백질을 생선하는 방법에 있어서, 상기의 방법은 EBV gp350/220유전자를 바쿨로바이러스 발현벡터 pBlueBacHisC속에 서브클로닝하여 EBV gp350/220 유전자 및 6-히스티딘 펩티드를 함유하는 플라스미드 pBac-TTI350을 형성하는 단계, 플라스미드 pBac-TTI350을 이용하여 적어도 EBV gp350/220단백질 및 6-히스티딘 펩티드를 암호화하는 CNA로 바이러스의 유전자를 치환하는 단계, EBV gp350/220유전자를 포함하는 바이러스로 곤충세포를 트랜스펙션시키는 단계, 트랜스펙션된 곤충세포를 수거하는 단계, 프랜스팩션된 곤충세포로부터 EBV gp350/220 단백질을 분리하는 단계, 수지가 6-히스티딘 펩티드에 대한 친화성을 갖는 컬럼에서 EBV gp350/220단백질을 정제하는 단계, 및 6-히스티딘 펩티드로부터 EBV gp350/220단백질을 분리하는 단계로 이루어지는 것을 특징으로 하는 방법In a method of processing substantially pure EBV gp350 / 220 protein, the method above subclones the EBV gp350 / 220 gene into the baculovirus expression vector pBlueBacHisC, which contains a plasmid pBac containing the EBV gp350 / 220 gene and 6-histidine peptide. Forming a TTI350, replacing the gene of the virus with a CNA encoding at least EBV gp350 / 220 protein and 6-histidine peptide using plasmid pBac-TTI350, insect cells with a virus comprising the EBV gp350 / 220 gene Transfecting, harvesting the transfected insect cells, separating the EBV gp350 / 220 protein from the transfected insect cells, EBV in a column in which the resin has affinity for 6-histidine peptide purifying the gp350 / 220 protein, and separating the EBV gp350 / 220 protein from the 6-histidine peptide. A way that 제21항의 방법에 의하여 생성된 단백질Protein produced by the method of claim 21 제21항에 있어서, EBV gp350/220유전자는 시그날 단백질을 코딩하는 아미노말단 서열이 결핍된 것을 특징으로 하는 방법The method of claim 21, wherein the EBV gp350 / 220 gene lacks an amino terminal sequence that encodes a signal protein. 제23항의 방법에 의하여 생성된 단백질Protein produced by the method of claim 23 실질적으로 순수한 EBV gp350/220단백질을 생성하는 방법에 있어서, 상기 방법은 EBV gp350/220 및 6-히스티딘 폴리펩티드를 암호화하는 유전자를 함유하는 바이러스를 이용하고, 상기의 방법은 곤충세포를 상기의 바이러스로 트랜스펙션시키고, 트랜스펙션된 곤충세로를 수거하고, 트랜스펙션된 곤충세포로부터 EBV gp350/220단백질 및 6-히스티딘 폴리펩티드를 분리하고, 수지가 6-히스티딘 ㅔㅂ티드에 대한 친화성을 갖는 컬럼에서 EBV gp350/220단백질 및 6-히스티딘 폴리펩티드를 정제하는 것으로 이루어지는 것을 특징으로 하는 방법In a method for producing substantially pure EBV gp350 / 220 protein, the method uses a virus containing a gene encoding EBV gp350 / 220 and a 6-histidine polypeptide, and the method uses insect cells as the virus. Transfected, harvested transfected insect verticals, isolate EBV gp350 / 220 protein and 6-histidine polypeptide from transfected insect cells, and the resin has affinity for 6-histidine peptide Purifying the EBV gp350 / 220 protein and 6-histidine polypeptide in a column 제25항의 방법에 의해 생성된 EBV gp350/220단백질EBV gp350 / 220 protein produced by the method of claim 25 EBV감염으로부터 포유동물에 보호하는 방법에 있어서, 제약학적으로 허용가능한 담체와 혼합된 제22항, 제24항 또는 제26항의 폴리펩티드의 면역원성 양을 함유하는 백신조성물의 면역학적으로 유효한 투여량을 상기 포유동물에 투여하는 것으로 이루어지는 것을 특징으로 하는 방법In a method of protecting a mammal from an EBV infection, an immunologically effective dose of a vaccine composition containing an immunogenic amount of the polypeptide of claim 22, 24 or 26 mixed with a pharmaceutically acceptable carrier is determined. Administering to said mammal ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950703810A 1993-03-12 1994-03-11 RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE KR960700749A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3118693A 1993-03-12 1993-03-12
US08/031186 1993-03-12
PCT/US1994/002637 WO1994020138A1 (en) 1993-03-12 1994-03-11 Recombinant epstein-barr virus protein and its use in vaccine

Publications (1)

Publication Number Publication Date
KR960700749A true KR960700749A (en) 1996-02-24

Family

ID=21858082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703810A KR960700749A (en) 1993-03-12 1994-03-11 RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE

Country Status (6)

Country Link
EP (1) EP0690917A4 (en)
JP (1) JPH08507442A (en)
KR (1) KR960700749A (en)
AU (1) AU681131B2 (en)
CA (1) CA2156719A1 (en)
WO (1) WO1994020138A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259306A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
GB0210682D0 (en) 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (en) * 1984-08-23 1991-08-29 Hans Joachim Wolf DNA SEQUENCES OF THE EBV GENOME, RECOMBINANT DNA MOLECULES, METHOD FOR THE PRODUCTION OF EBV-RELATED ANTIGENS, DIAGNOSTIC COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ANTIGENS.

Also Published As

Publication number Publication date
EP0690917A4 (en) 1996-05-22
EP0690917A1 (en) 1996-01-10
CA2156719A1 (en) 1994-09-15
JPH08507442A (en) 1996-08-13
AU681131B2 (en) 1997-08-21
WO1994020138A1 (en) 1994-09-15
AU6404594A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
DE69332485T2 (en) Immunomodulatory peptides
EP0835315A4 (en) Vaccine for porcine reproductive and respiratory syndrome virus
NO329875B1 (en) Isolated DNA sequence encoding swine reproductive and respiratory syndrome virus (PRRSV), a composition comprising the polypeptides encoded therein, a composition for inducing antibodies against PRRSV, use of a vaccine preparation composition and methods for distinguishing PRRSV strain ISU. 55 from other PRRSV strains.
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
KR910001060A (en) New compounds
AU585512B2 (en) Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella and eimeria necatrix
KR950704489A (en) INTERFERON TAU COMPOSITIONS AND METHODS OF USE
RU2001107969A (en) IMMUNODOMINANT ANTIGENIC PROTEIN MASS OF 120 KDA AND THE EHRLICHIA CANIS GENE
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
EP0294469A4 (en) Vaccines and diagnostic assays for haemophilus influenzae.
ATE104349T1 (en) VACCINE AGAINST COCCIDIOSIS.
KR960700749A (en) RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE
EP1512693A3 (en) Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof
DK35891D0 (en) PRACTICALLY TAKEN PURE, ANTIGENIC PEPTIDE OR PROTEIN WITH AN EPITOP OF HAEMOPHILUS INFLUENZAE, ITS PREPARATION AND USE
DE69935599D1 (en) MODIFIED HCV PEPTIDE VACCINES
KR101937792B1 (en) A Vaccine Composition For Foot-and-mouth disease Comprising Novel Recombinant Antigenic Protein
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
EP0227604A2 (en) Use of oligopeptides in the treatment of viral infections
Bose et al. C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein
RU94045154A (en) Polypeptides, their fragments and variants, preparation, dna, vector, cell, method of polypeptide producing, vaccines, protection method, antibody and its fragment, their use, dna use, method of antigen identification
Braciak et al. Vector-derived expression of recombinant rat interleukin-6
TWI776048B (en) Recombinant protein for preventing swine fever virus infection and composition and cell comprising the same.
WO2023117742A1 (en) Vaccine compositions and their use
GB2341606A (en) Glycosylation peptides
EP0953642A4 (en) Antigenic protein originating in infectious laryngotracheitis virus

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid